Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

Nature communications·2025

Same author

Conventional PCR-based versus next-generation sequencing-based approach for T-cell receptor γ gene clonality assessment in mature T-cell lymphomas: A phase 3 diagnostic accuracy study.

Journal of biological methods·2024

Same author

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.

The Lancet. Oncology·2023

Same author

The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.

Best practice & research. Clinical haematology·2023

Same author

A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2023

Search research articles

Related Experiment Video

Updated: May 29, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Targeted molecular therapy in peripheral T-cell lymphomas.

Fernando Roncolato¹, Anna Gazzola, Pier Luigi Zinzani

¹Department of Haematology, St George Hospital, Sydney, Australia.

Expert Review of Hematology

|September 24, 2011

Summary

Targeted therapy offers new hope for peripheral T-cell lymphomas (PTCLs), a rare cancer. Researchers are exploring novel drugs and pathways to improve treatment efficacy beyond traditional chemotherapy for these aggressive lymphomas.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Peripheral T-cell lymphomas (PTCLs) are rare, aggressive blood cancers with limited treatment options.
Current chemotherapy regimens effective for B-cell lymphomas show reduced efficacy in PTCLs.
A deeper understanding of PTCL biology necessitates the development of alternative therapeutic strategies.

Purpose of the Study:

To review the current literature on targeted therapy for PTCLs.
To discuss emerging molecular targets and pathways for novel PTCL treatments.
To explore potential future opportunities in PTCL targeted therapy based on recent advancements.

Main Methods:

Comprehensive literature review of targeted therapies in PTCL.
Analysis of recent advancements in understanding PTCL biology.
Discussion of clinical evidence for novel agents and pathways.

Main Results:

Several molecular targets and pathways, including surface antigens and tyrosine kinases, are being investigated for PTCL treatment.
Histone deacetylase inhibitors, proteasome inhibitors, and pralatrexate have shown efficacy in PTCL therapy.
Tyrosine kinase inhibitors show promise, supported by biological rationale and early clinical data.

Conclusions:

Targeted therapies represent a promising frontier for improving outcomes in PTCL.
Novel agents like histone deacetylase inhibitors and tyrosine kinase inhibitors warrant further clinical investigation.
Continued research into PTCL biology will uncover new therapeutic opportunities.